# RenBio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/renbio

- Industry: Biotechnology
- Headquarters: New York, US
- Website: www.renbio.com
- Total disclosed funding: $24M
- Latest round: Series A (May 20, 2021)
- Investors on record: 1

## About

RenBio, Inc., based in the US, specializes in the development of next-generation DNA Therapeutics. The company focuses on delivering innovative therapeutic solutions through its proprietary technology aimed at combating infectious diseases.RenBio, Inc. was founded in 2016 and is headquartered in New York, US. It operates within the biotechnology sector, focusing on advanced therapeutic solutions. The company has participated in five total deals, with the most recent deal occurring on October 12, 2022, when it raised USD 1.00 mn in a GRANT from the Defense Advanced Research Projects Agency. The total amount raised by the company amounts to USD 24.00 mn.RenBio DNA Therapeutics specializes in next-generation medicinal products, primarily through its proprietary Make Your Own (MYO) Technology. This innovative platform focuses on delivering therapeutic-encoding 'bioblueprints' via modified intramuscular injections, allowing muscle cells to produce disease-fighting therapeutics within the patient's body. The company aims to modernize the administration of antibody and therapeutic protein treatments to enhance efficacy, durability, and cost-effectiveness, addressing significant barriers in the current healthcare landscape. RenBio’s products target a range of conditions, particularly infectious diseases, by focusing on delivering antiviral antibodies and improving therapeutic protein dosing regimens. The geographical markets for these products extend beyond the United States, potentially reaching diverse international markets, where there is a pressing need for advanced therapeutic solutions.RenBio generates revenue through its innovative therapeutic solutions, which are primarily offered via partnerships with healthcare providers and research institutions. These transactions typically involve agreements wherein clients engage with RenBio to access their MYO Technology and associated therapeutic blueprints. The pricing structure for their offerings is based on the complexity and scope of the services provided, potentially involving subscription models for ongoing access to the technology or one-time fees for specific therapies. RenBio’s flagship MYO Technology plays a crucial role in its revenue model, as it represents their core service that enables the production of customized therapeutics directly in patients. The company fosters collaborations that may also include performance-based agreements contingent on therapeutic outcomes, thereby aligning its financial success with the effectiveness of its services.RenBio plans to leverage its recent funding of USD 1.00 mn, obtained in October 2022, to further develop its MYO Technology and expand its product offerings. The company is actively designing new therapeutic solutions aimed at infectious diseases, seeking to launch several new products in the coming years. In addition, RenBio is targeting expansion into international markets where there is a significant need for its advanced therapeutic solutions, with plans to establish partnerships in Europe and Asia by 2025.

## Funding rounds

- Series A, May 20, 2021, $24M — Ruentex Group

## Investors

- Ruentex Group (https://capitalatlas.ai/funds/ruentex-group) — Series A